Long-term Survivorship and Outcomes of Patients Without Dysplasia Undergoing Capsular Repair During Primary Hip Arthroscopy for Femoroacetabular Impingement Syndrome
- PMID: 38828912
- DOI: 10.1177/03635465241248603
Long-term Survivorship and Outcomes of Patients Without Dysplasia Undergoing Capsular Repair During Primary Hip Arthroscopy for Femoroacetabular Impingement Syndrome
Abstract
Background: There is a paucity of literature evaluating long-term outcomes and survivorship of patients undergoing primary hip arthroscopy with capsular repair for femoroacetabular impingement syndrome (FAIS).
Purpose: To report 10-year survivorship and patient-reported outcomes (PROs) after primary hip arthroscopy with capsular repair for FAIS and evaluate the effect of capsular repair in patients at the highest risk for conversion to arthroplasty.
Study design: Cohort study; Level of evidence, 3.
Methods: Data were prospectively collected and retrospectively reviewed on all patients undergoing primary hip arthroscopy with capsular repair between October 2008 and February 2011. Patients with a minimum 10-year follow-up on the modified Harris Hip Score (mHHS), Nonarthritic Hip Score (NAHS), and visual analog scale for pain (VAS) scores were selected. The preoperative and minimum 10-year follow-up Hip Outcome Score-Sports Specific Subscale (HOS-SSS) scores were also reported, if available. Patients with ipsilateral hip surgery, worker's compensation, Tönnis osteoarthritis grade >1, and hip dysplasia (lateral center-edge angle <25°) were excluded. Survivorship, PROS, and clinical benefit-minimal clinically important difference (MCID) and Patient Acceptable Symptom State (PASS)-were reported. An additional propensity-matched subanalysis was performed on patients at the highest risk for conversion to arthroplasty, comparing patients undergoing capsular repair to patients with unrepaired capsules.
Results: A total of 145 (n = 130 patients) out of 180 eligible hips (n = 165 patients) had a minimum 10-year follow-up (80.6%). Also, 126 hips (86.9%) belonged to women, and 19 hips (13.1%) belonged to men. The mean patient age was 30.3 ± 12.9 years. The survivorship rate was 91% at the 10-year follow-up. The cohort experienced significant improvements (P < .001) in the mHHS, NAHS, HOS-SSS, and VAS for pain scores. Moreover, the cohort achieved high rates of the PASS for the mHHS (89.8%), high rates of the MCID for the mHHS (82.4%), and high rates of the MCID for VAS for pain (80.6%) scores. In the propensity-matched subanalysis performed on patients with the highest risk for arthroplasty, 29 hips with capsular repair were matched to 81 hips with unrepaired capsules. While both groups experienced significant improvements in all PROs (P < .05), the group without capsule repair trended toward a higher conversion to arthroplasty rate when compared with the repair group. In addition, an odds ratio was calculated for the likelihood of converting to arthroplasty after having an unrepaired capsule compared with capsular repair (2.54 [95% CI, 0.873-7.37]; P = .087).
Conclusion: Patients undergoing primary hip arthroscopy with capsular repair experienced a high survivorship rate of 91% at a minimum 10-year follow-up. Patients who did not convert to arthroplasty saw favorable improvements in PROs and achieved high clinical benefit rates. In addition, among those patients at the highest risk for conversion to arthroplasty, a trend toward greater survivorship was observed with capsular repair.
Keywords: capsular repair; hip arthroscopy; long-term outcomes; survivorship.
Conflict of interest statement
One or more of the authors has declared the following potential conflict of interest or source of funding: The research reported in this article was supported by the IIRR-01508 study funding from Arthrex. B.G.D. has had ownership interests in the American Hip Institute, Hinsdale Orthopedic Associates, Hinsdale Orthopedic Imaging, SCD#3, North Shore Surgical Suites, Munster Specialty Surgery Center; research support from Arthrex, Stryker, Smith & Nephew, and Ossur; consulting fees from Arthrex, Medacta, Stryker, SI-Bone Inc; has received educational support from Arthrex, Stryker, St. Alexius Medical Center; speaking fees from Arthrex; travel and lodging from Arthrex, Stryker; food and beverage from Arthrex, DJO Global, Medacta, Stryker, Zimmer Biomet, DePuy Synthes Sales, Medtronic, Trice Medical, Medwest Associates, SI-Bone Inc, Xiros Inc, Intellijoint Surgical Inc, Electronic Waveform Lab Inc; royalties from Arthrex, DJO Global, Medacta, Stryker, Orthomerica. Dr. Domb is Director of Hip Preservation at St. Alexius Medical Center, board member for the American Hip Institute Research Foundation, AANA Learning Center Committee, the Journal of Hip Preservation Surgery, Journal of Arthroscopy, AOSSM Research Committee, ISHA Executive Board. The American Hip Institute Research Foundation (American Orthopedic Foundation) funds research and is where our study was performed. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.
Similar articles
-
Ten-Year Survivorship, Outcomes, and Sports Participation in Athletes After Primary Hip Arthroscopy for Femoroacetabular Impingement Syndrome.Am J Sports Med. 2023 Jul;51(9):2383-2395. doi: 10.1177/03635465231180305. Epub 2023 Jun 27. Am J Sports Med. 2023. PMID: 37366226
-
Hip Arthroscopic Surgery in the Context of Femoroacetabular Impingement Syndrome, Labral Tear, and Acetabular Overcoverage: Minimum 5-Year Outcomes With a Subanalysis Against Patients Without Overcoverage.Am J Sports Med. 2021 Jan;49(1):55-65. doi: 10.1177/0363546520969985. Epub 2020 Nov 25. Am J Sports Med. 2021. PMID: 33237818
-
Revision Hip Arthroscopy in the Borderline Dysplastic Population: Reporting Outcomes With Minimum 2-Year Follow-up, With a Subanalysis Against a Propensity-Matched Nondysplastic Control Group.Am J Sports Med. 2021 Jan;49(1):66-75. doi: 10.1177/0363546520969878. Epub 2020 Nov 20. Am J Sports Med. 2021. PMID: 33216619
-
Capsular Repair Is Associated With Lower Revision Rates Yet Similar Clinical Outcomes and Arthroplasty Conversion 5 Years After Hip Arthroscopy: A Systematic Review.Arthroscopy. 2023 Aug;39(8):1882-1891.e1. doi: 10.1016/j.arthro.2023.04.016. Epub 2023 May 3. Arthroscopy. 2023. PMID: 37146665
-
Hip Capsular Repair Results in Improved Patient-Reported Outcomes and Survivorship: A Systematic Review of the Literature.Arthroscopy. 2023 Feb;39(2):488-497. doi: 10.1016/j.arthro.2022.11.013. Epub 2022 Nov 14. Arthroscopy. 2023. PMID: 36395962
Cited by
-
Arthroscopic Management of Femoroacetabular Impingement: Current Concepts.J Clin Med. 2025 Feb 21;14(5):1455. doi: 10.3390/jcm14051455. J Clin Med. 2025. PMID: 40094916 Free PMC article. Review.
-
Concurrent Arthroscopic Revision of the Hip Labral and Anterior Capsular Reconstruction Utilizing Iliotibial Band Autograft.Arthrosc Tech. 2024 Dec 13;14(5):103366. doi: 10.1016/j.eats.2024.103366. eCollection 2025 May. Arthrosc Tech. 2024. PMID: 40548006 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous